[go: up one dir, main page]

MX2016016994A - Metodos para tratar, diagnosticar y pronosticar una malignidad hematologica. - Google Patents

Metodos para tratar, diagnosticar y pronosticar una malignidad hematologica.

Info

Publication number
MX2016016994A
MX2016016994A MX2016016994A MX2016016994A MX2016016994A MX 2016016994 A MX2016016994 A MX 2016016994A MX 2016016994 A MX2016016994 A MX 2016016994A MX 2016016994 A MX2016016994 A MX 2016016994A MX 2016016994 A MX2016016994 A MX 2016016994A
Authority
MX
Mexico
Prior art keywords
htr
hematological malignancy
hematological
type
htr type
Prior art date
Application number
MX2016016994A
Other languages
English (en)
Other versions
MX362049B (es
Inventor
Muñoz Risueño Ruth
Original Assignee
Inst De Recerca Contra La Leucèmia Josep Carreras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Recerca Contra La Leucèmia Josep Carreras filed Critical Inst De Recerca Contra La Leucèmia Josep Carreras
Publication of MX2016016994A publication Critical patent/MX2016016994A/es
Publication of MX362049B publication Critical patent/MX362049B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G01N33/57505—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un inhibidor del receptor de serotonina (5-HTR) seleccionado del grupo que consiste de un inhibidor del 5-HTR tipo 1 y un inhibidor del 5-HTR tipo 2 para uso en la prevención y/o tratamiento de una malignidad hematológica. Adicionalmente, la invención se refiere a métodos in vitro para la identificación o aislamiento de una célula maligna de una malignidad hematológica o para diagnosticar una malignidad hematológica con base en la detección de la expresión del 5-HTR tipo 1 y/o 5-HTR tipo 2. Además, la invención se refiere a métodos in vitro para determinar el pronóstico, para monitorear el efecto de una terapia o para diseñar una terapia personalizada en un sujeto que sufre de una malignidad hematológica con base en la determinación de los niveles del 5-HTR tipo 1 y/o 5-HTR tipo 2.
MX2016016994A 2014-06-27 2015-06-26 Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica. MX362049B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382249.2A EP2959904A1 (en) 2014-06-27 2014-06-27 Methods for treating, diagnosing and prognosing a haematological malignancy
PCT/EP2015/064571 WO2015197839A1 (en) 2014-06-27 2015-06-26 Methods for treating, diagnosing and prognosing a haematological malignancy

Publications (2)

Publication Number Publication Date
MX2016016994A true MX2016016994A (es) 2017-06-09
MX362049B MX362049B (es) 2019-01-04

Family

ID=51162662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016994A MX362049B (es) 2014-06-27 2015-06-26 Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.

Country Status (15)

Country Link
US (4) US10195207B2 (es)
EP (2) EP2959904A1 (es)
JP (2) JP2017526629A (es)
KR (1) KR102628235B1 (es)
CN (1) CN106471373B (es)
AU (2) AU2015279105B2 (es)
BR (1) BR112016029562B1 (es)
CA (1) CA2953272C (es)
DK (1) DK3160472T3 (es)
ES (1) ES2796056T3 (es)
IL (1) IL249579B (es)
MX (1) MX362049B (es)
RU (1) RU2727418C2 (es)
WO (1) WO2015197839A1 (es)
ZA (1) ZA201700080B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2954072T3 (es) * 2016-07-28 2023-11-20 Jiangsu Yahong Meditech Co Ltd Usos de inhibidores de la dopamina beta-hidroxilasa (DBH) para el tratamiento del cáncer
EP3348266A1 (en) * 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer
JP7002245B2 (ja) * 2017-08-10 2022-01-20 シスメックス株式会社 血液分析装置、血液分析方法およびプログラム
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
KR20200110671A (ko) 2018-01-18 2020-09-24 레우코스 바이오테크 에스. 엘. 아포몰핀·팔미트산 공결정 고체 입자 결정질 형태
US11034751B1 (en) 2018-01-30 2021-06-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using serotonin receptor inhibitors
CN111257558B (zh) * 2020-01-19 2021-08-24 江苏省人民医院（南京医科大学第一附属医院） 基于机器学习的慢性淋巴细胞白血病肿瘤细胞识别方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
NL300886A (es) 1962-11-23
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
KR20040055311A (ko) * 2002-12-20 2004-06-26 주식회사 피앤아이 컨설팅 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템
US20060234240A1 (en) * 2003-02-17 2006-10-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
WO2008098351A1 (en) * 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
WO2008146101A1 (en) 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases
US8293239B2 (en) * 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2015079439A1 (en) * 2013-11-26 2015-06-04 Technion Research And Development Foundation Limited Neuronal modulation
US20150197839A1 (en) * 2014-01-13 2015-07-16 Maria Celeste Rellamas Tria Forming conductive pattern using titania sol-gel

Also Published As

Publication number Publication date
EP2959904A1 (en) 2015-12-30
CA2953272C (en) 2022-10-04
IL249579A0 (en) 2017-02-28
EP3160472A1 (en) 2017-05-03
MX362049B (es) 2019-01-04
KR102628235B1 (ko) 2024-01-22
US20210228593A1 (en) 2021-07-29
AU2015279105B2 (en) 2019-10-03
RU2016147748A (ru) 2018-08-03
BR112016029562A2 (pt) 2017-08-22
US11337984B2 (en) 2022-05-24
RU2016147748A3 (es) 2019-02-13
CA2953272A1 (en) 2015-12-30
AU2020200010B2 (en) 2020-11-19
JP6846551B2 (ja) 2021-03-24
IL249579B (en) 2019-03-31
DK3160472T3 (da) 2020-06-02
US20220323456A1 (en) 2022-10-13
EP3160472B1 (en) 2020-03-11
ES2796056T3 (es) 2020-11-25
BR112016029562B1 (pt) 2021-07-06
JP2017526629A (ja) 2017-09-14
CN106471373B (zh) 2019-08-23
US20170143735A1 (en) 2017-05-25
AU2020200010A1 (en) 2020-01-30
AU2015279105A1 (en) 2016-12-15
KR20170021253A (ko) 2017-02-27
ZA201700080B (en) 2019-04-24
JP2020097608A (ja) 2020-06-25
RU2727418C2 (ru) 2020-07-21
US20190343843A1 (en) 2019-11-14
US10195207B2 (en) 2019-02-05
WO2015197839A1 (en) 2015-12-30
CN106471373A (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
MX362049B (es) Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MX2015000008A (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX383296B (es) Vigilancia del tratamiento y pronóstico de los trastornos de la proliferación utilizando inhibidores de la vía de hedgehog.
MX388405B (es) Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
MX355632B (es) Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres.
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
AR102146A1 (es) Métodos de selección de tensioactivos para humedecer alteraciones en formaciones subterráneas
CL2016002419A1 (es) Métodos para determinar la probabilidad de padecer cáncer de próstata que comprende inmunoensayos de antígenos específicos de próstata
CR20160132A (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2017005126A (es) Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2018000528A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MA40636A (fr) Procédés pour détecter le cancer de la prostate
ES2672989T3 (es) FALZ para su uso como diana para terapias para tratar el cáncer
WO2014071218A3 (en) Biomarkers for breast cancer and methods of using same

Legal Events

Date Code Title Description
FG Grant or registration